The process is approved and in use in Europe and awaiting trial results and FDA approval for the US. An actual procedure with a open heart surgery use can be seen here. Private investors have recently contributed financing for the product. BD
Pluromed's lead product, LeGoo" temporary vascular occluder, is already approved for human use in Europe. Vogel summarizes the feedback he is getting from European surgeons using LeGoo" in their clinical practice as follows: "For years, surgeons have been looking for a simpler,
atraumatic method to control bleeding during surgery, but it simply didn't exist... Now, with LeGoo, surgeons can "clamp" without a clamp, using a phase-changing liquid/gel . No more squeezing and pressurizing, and thus no more fear of damaging fragile or calcified blood vessels. L eGoo" has the potential to revolutionize the practice of surgery." Proceeds from the Series B funding will be used to continue clinical and marketing studies in Europe and Canada, where the company has products approved for human use, and to further the FDA approval process in the United States.